| Mon, Nov 9, 2009 | | | Successful Pharmaceutical Company Mergers: Abbott Labs Is Leader Wall Street Transcript (Mon 2:31pm)
| | | A Bear in the Bullpen: 3 Power Ratings Stocks Ready to Drop TradingMarkets.com (Mon 9:41am)
| | Sat, Nov 7, 2009 | | | Elan, Biogen change Tysabri label due to PML risk at Reuters (Sat, Nov 7)
| | Tue, Nov 3, 2009 | | | Nice Quarter, Teva. What Will You Buy Next? at Motley Fool (Tue, Nov 3)
| | | UPDATE - J&J slashing workforce, cites cost of drug research at Reuters (Tue, Nov 3)
| | | Johnson & Johnson to cut up to 8,200 jobs at MarketWatch (Tue, Nov 3)
| | Fri, Oct 30, 2009 | | | Healthcare Earnings Are Coming Into Focus at Investopedia (Fri, Oct 30)
| | Thu, Oct 29, 2009 | | | Elan Corporation Plc Announces Expiration of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011 Business Wire (Thu, Oct 29)
| | | 3 Stocks in a Tailspin at Motley Fool (Thu, Oct 29)
| | | UPDATE - EU agency reports 24th case of Tysabri infection at Reuters (Thu, Oct 29)
| | | 5-Star Stocks Poised to Pop: MEMC at Motley Fool (Thu, Oct 29)
| | | More PML Troubles for Biogen, Elan MS Drug: Biobuzz at TheStreet.com (Thu, Oct 29)
| | | Elan downgraded by UBS Briefing.com (Thu, Oct 29)
| | Wed, Oct 28, 2009 | | | FDA Approval for GlaxoSmithKline Zacks.com (Wed, Oct 28)
| | Tue, Oct 27, 2009 | | | Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease Business Wire (Tue, Oct 27)
| | | Targeting Tysabri at Forbes.com (Tue, Oct 27)
| | | Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com GlobeNewswire (Tue, Oct 27)
| | Mon, Oct 26, 2009 | | | For Tysabri, 23 Is 10 Too Many at Motley Fool (Mon, Oct 26)
| | | 5 Superball Stocks at Motley Fool (Mon, Oct 26)
| | | J&J CEO's Lower-Risk Alternative to Acquisitions at The Wall Street Journal Online (Mon, Oct 26)
| Add ELN News to My Yahoo!:

| |
|